Gil Omenn is Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan, Ann Arbor, USA. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. He was Dean of the School of Public Health, and Professor of Medicine and Environmental Health, University of Washington, Seattle, 1982-1997. He is the leader of the global Human Proteome Project (HPP) of the Human Proteome Organization (HUPO). His current research is focused on proteogenomics of alternative splicing in cancers. Splice variants are a major source of protein diversity in multi-cellular organisms with multi-exonic genes. Splice isoforms are good candidates for more specific biomarkers and therapeutic targets. He is author of 548 publications. Omenn has visited China 12 times since 1976. He is an honorary faculty of Peking Union Medical College, affiliate faculty of the Institute for Systems Biology in Seattle, member of the U.S. National Academy of Medicine, past president of the American Association for the Advancement of Science, board member of the Weizmann Institute of Science in Israel, and a director of several biotech companies. He served as a White House Fellow at the U.S. Atomic Energy Commission and as associate director of the White House Office of Science & Technology Policy and Office of Management & Budget. He earned the B.A. from Princeton University, M.D. from Harvard Medical School, and PhD in genetics from University of Washington. He is a musician and tennis player.

Dr. Omenn's research focuses on proteo-genomics of cancers and proteomics informatics. He long chaired and remains active in the Human Proteome Organization (HUPO) global Human Proteome Project (www.thehpp.org). There are datasets for application of analytical tools, and there are research teams eager to engage in collaborative studies in the Chromosome-centric HPP and Biology and Disease-driven HPP initiatives. He is a co-founder of the Consortium for Clinical Characterization of Covid-19 using Electronic Health Records (4CE) organized by the i2b2tranSMART Foundation and Harvard colleagues. He has long-standing interests in mechanisms of genetic predispositions to risks from environmental and occupational exposures (eco-genetics) and science-based risk analyses.